Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Corporate Breaking News

Home : Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Sep 12 2019	Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001
BASEL, Switzerland, Sept. 12, 2019 /PRNewswire/ -- Strekin AG (www.strekin.com), a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized,...


Source:https://www.prnewswire.com:443/news-releases/strekin-ag-announces-completion-of-patient-recruitment-in-the-restore-phase-3-clinical-study-of-str001-300915265.html

Related News
» Strekin AG anuncia conclusión de reclutamiento en el estudio clínico RESTORE de fase 3 del STR001 » Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress